<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="en">
	<front>
		<journal-meta>
			<journal-id journal-id-type="publisher-id">AJMB</journal-id>
			<journal-title>Avicenna Journal of Medical Biotechnology</journal-title>
			<issn pub-type="ppub">2008-2835</issn>
			<issn pub-type="epub">2008-4625</issn>
			<publisher>
				<publisher-name>Avicenna Research Institute</publisher-name>
			</publisher>
		</journal-meta>
		<article-meta>
			<article-id pub-id-type="publisher-id">AJMB-1-19</article-id>
			<article-categories>
				<subj-group subj-group-type="heading">
					<subject>Original Article</subject>
				</subj-group>
			</article-categories>
			<title-group>
				<article-title>Generation and Characterization of Mouse Hybridomas Secreting Monoclonal Antibodies Specific for Human IgG3</article-title>
			</title-group>
			<contrib-group>
				<contrib contrib-type="author">
					<name>
						<surname>Hajighasemi</surname>
						<given-names>Fatemeh</given-names>
					</name>
					<xref ref-type="aff" rid="AF0001">1</xref>
					<xref ref-type="aff" rid="AF0002">2</xref>
				</contrib>
				<contrib contrib-type="author" corresp="yes">
					<name>
						<surname>Shokri</surname>
						<given-names>Fazel</given-names>
					</name>
					<xref ref-type="aff" rid="AF0001">1</xref>
					<xref ref-type="aff" rid="AF0003">3</xref>
					<xref ref-type="corresp" rid="cor1">&#x002A;</xref>
				</contrib>
			</contrib-group>
			<aff id="AF0001">
				<label>1</label>Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran</aff>
			<aff id="AF0002">
				<label>2</label>Department of Immunology, School of Medicine, Shahed University, Tehran, Iran</aff>
			<aff id="AF0003">
				<label>3</label>Monoclonal Antibody Research Center, Avecinna Research Center ACECR, Tehran, Iran</aff>
			<author-notes>
				<corresp id="cor1">
				<label>&#x002A;</label>
				<bold>Corresponding author:</bold> Fazel Shokri, Ph.D., Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. P.O. Box: 6446-14133. <bold>Tel:</bold> +98 21 66462268. <bold>Fax:</bold> +98 21 66462267. <bold>E-mail:</bold> <email xlink:href="fshokri@sina.tums.ac.ir">fshokri@sina.tums.ac.ir</email>,<email xlink:href="fazshok@yahoo.com">fazshok@yahoo.com</email>
				</corresp>
			</author-notes>
			<pub-date pub-type="ppub">
				<season>April-June</season>
				<year>2009</year>
			</pub-date>
			<volume>1</volume>
			<issue>1</issue>
			<fpage>19</fpage>
			<lpage>26</lpage>
			<history>
				<date date-type="received">
					<day>04</day>
					<month>04</month>
					<year>2009</year>
				</date>
				<date date-type="accepted">
					<day>20</day>
					<month>04</month>
					<year>2009</year>
				</date>
			</history>
			<permissions>
			<copyright-statement>Copyright &#x00A9; 2009 Avicenna Research Institute</copyright-statement>
				<copyright-year>2009</copyright-year>
				<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
					<p>This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.</p>
				</license>
			</permissions>
			<abstract>
				<p>Mammalians express several subclasses of the IgG molecule. In human being there are four homologous IgG subclasses, each of which is structurally unique and has different functions. Quantification of IgG subclasses is fundamental to clinical assessment and diagnosis of many diseases as such assessments depends on the availability of subclassspecific antibodies (Abs), particularly monoclonal antibodies (MAbs). In the present study, we produced and characterized two murine MAbs specific for human IgG3 molecule. These MAbs were obtained by the fusion of myeloma cells with splenocytes from Balb/c mice immunized with heavy chain of a human IgG3 myeloma protein. Fused cells were selected in hypoxanthine, aminopterine and thymidine (HAT) medium and cloned by limiting dilution assay. Ab-secreting cells were screened by enzyme-linked immunosorbent assay (ELISA) and the specificity of secreted MAbs was further analyzed, using a panel of purified myeloma proteins by ELISA and immunoblotting. Two stable hybridomas designated 1F18G7 and 1F18A11 were obtained secreting MAbs specific for Fc fragment of human IgG3. None of these MAbs showed cross-reactivity with other immunoglobulin isotypes derived from human and nine other animals, except 1F18A11 which displayed a weak cross-reactivity with only dog serum. Immunoblotting results indicate that these MAbs react with linear epitope(s) located in the heavy chain of human IgG3 molecules. The affinity constant of 1F18G7 and 1F18A11 MAbs was found to be 0.81&#x00D7;10<sup>9</sup> Mol <sup>&#x2212;1</sup> and 0.71&#x00D7;10<sup>9</sup> Mol <sup>&#x2212;1</sup>, respectively, as measured by ELISA. These two MAbs with relatively high affinity can be useful tools for quantification of IgG3 subclass levels in human serum.</p>
			</abstract>
			<kwd-group>
				<kwd>Heavy chain</kwd>
				<kwd>Human IgG3</kwd>
				<kwd>Immunoglobulin</kwd>
				<kwd>Isotype</kwd>
				<kwd>Light chain</kwd>
				<kwd>Monoclonal antibody</kwd>
			</kwd-group>
		</article-meta>
	</front>
	<body>
		<sec id="S0001" sec-type="intro">
			<title>Introduction</title>
			<p>Different IgG subclasses are preferentially produced in response to different anti-genic stimuli depending on the nature of the antigen (Ag) and the genetic background of the species (<xref ref-type="bibr" rid="CIT0001">1</xref>&#x2013;<xref ref-type="bibr" rid="CIT0003">3</xref>). Thus, while thymus-dependent protein Ags (TD) elicit predominantly IgG1 and IgG3 subclasses, thymus-independent (TI) polysaccharide Ags tend to induce IgG2 antibody response. The profile of the IgG subclass may also be indicative of the type of the implicated disease and its severity (<xref ref-type="bibr" rid="CIT0004">4</xref>&#x2013;<xref ref-type="bibr" rid="CIT0008">8</xref>). Analysis of the IgG subclass profiles to different antigens of a microorganism, reveals the kind of T helper associated response (<xref ref-type="bibr" rid="CIT0009">9</xref>) and also is helpful for designing a potential vaccine (<xref ref-type="bibr" rid="CIT0010">10</xref>).</p>
			<p>In human there are four IgG subclasses, each of which is structurally unique with different functions (<xref ref-type="bibr" rid="CIT0011">11</xref>). This is particularly evident concerning their ability to mediate complement activation and to bind Fc&#x03B3; receptors on the surface of cells involved in the immune response (<xref ref-type="bibr" rid="CIT0012">12</xref>&#x2013;<xref ref-type="bibr" rid="CIT0014">14</xref>). While there is more than 90% sequence homology between the constant domains of &#x03B3;<sub>1,</sub> &#x03B3;<sub>2,</sub> &#x03B3;<sub>3</sub> and &#x03B3;<sub>4</sub> heavy chains, more marked structural differences are present in the corresponding hinge region. IgG3 molecules have an extended hinge region relative to other subclasses (<xref ref-type="bibr" rid="CIT0011">11</xref>).</p>
			<p>In human there are four IgG subclasses, each of which is structurally unique with different functions (<xref ref-type="bibr" rid="CIT0011">11</xref>). This is particularly evident concerning their ability to mediate complement activation and to bind Fc&#x03B3; receptors on the surface of cells involved in the immune response (<xref ref-type="bibr" rid="CIT0012">12</xref>&#x2013;<xref ref-type="bibr" rid="CIT0014">14</xref>). While there is more than 90% sequence homology between the constant domains of &#x03B3;<sub>1,</sub> &#x03B3;<sub>2,</sub> &#x03B3;<sub>3</sub> and &#x03B3;<sub>4</sub> heavy chains, more marked structural differences are present in the corresponding hinge region. IgG3 molecules have an extended hinge region relative to other subclasses (<xref ref-type="bibr" rid="CIT0011">11</xref>).</p>
			<p>This proline-rich region confers higher flexibility and more susceptibility to proteolytic enzyme degradation to IgG3 molecule compared to other human IgG subclasses. Higher catalytic rate and stronger binding affinity to the Fc&#x03B3; receptors and the C1q complement component are also assumed to be associated to this unique character of IgG3 (<xref ref-type="bibr" rid="CIT0015">15</xref>). A single miss-sense mutation (L368P) in the CH3 region of the human IgG3 was shown to be associated with impaired secretion of intact and functional Ig (<xref ref-type="bibr" rid="CIT0016">16</xref>). Hydrophilicity and accessibility of most of the hinge amino acid residues have made this region highly immunogenic one to which most of the IgG3 specific MAbs have so far been developed.</p>
			<p>In the present study two MAbs specific to human IgG3 molecule were produced and characterized.</p>
		</sec>
		<sec id="S0002" sec-type="materials|methods">
			<title>Materials and Methods</title>
			<sec id="S20003">
				<title>Preparation of purified human IgG subclasses</title>
				<p>A panel of 27 different purified human IgG myeloma proteins of known IgG sub-classes and light chain types was employed in this study. These myeloma proteins, obtained from patients with multiple myeloma, were either purified by diethyl aminoethyl (DEAE) cellulose (Whatmann, UK) chromatography or by affinity chromatography using Staphylococcal protein A (SPA) or Streptococcal protein G (SPG) Sepharose 4B (Pharmacia, Sweden).</p>
				<p>The heavy chain and light chain isotypes and subclasses of myeloma were identified using isotype-specific mouse MAbs includeing: AF6 (IgM), 8a4 (IgG), 2D7 (IgA), JA11 (IgD), C4 (&#x03BB;), 6el (&#x03BA;), JL512 (IgG1), GOM2 (IgG2), ZG4 (IgG3) and RJ4 (IgG4), kindly provided by Professor R. Jefferis (Department of Immunology, University of Birmingham, UK).</p>
				<p>Polyclonal IgG was isolated from normal serum with SPG-Sepharose and polyclonal IgG3 was isolated, as breakthrough fraction, from polyclonal IgG by SPA-Sepharose column. Fc, Fab and F (ab&#x0027;) 2 fragments were prepared from several purified human myeloma proteins of each of the IgG subclasses, by pepsin and papain digestion (<xref ref-type="bibr" rid="CIT0017">17</xref>). Digested fragments were isolated by affinity chromatography with SPA-Sepharose column.</p>
			</sec>
			<sec id="S20004">
				<title>Animal sera</title>
				<p>Sera from human and nine animals were obtained prepared from their clotted blood. The animals used in this study were chicken, rabbit, guinea pig, cat, dog, sheep, goat, horse and monkey. The human serum was used as the control.</p>
			</sec>
			<sec id="S20005">
				<title>Generation and selection of hybridomas</title>
				<p>Balb/c mice (8&#x2013;12 weeks of age) were immunized with four intraperitoneal injections of heavy chain from an IgG3 myeloma protein emulsified in Freund&#x0027;s complete adjuvant (Sigma, U.S.A) (first injection) or incomplete adjuvant (Sigma) (other injections) (50 &#xB5;<italic>g</italic> every 2 weeks).</p>
				<p>Three days after the last injection, spleen cells were fused with SP2/0 myeloma cells (NCBI C129, National Cell Bank of Iran, Pasteur Institute of Iran, Tehran), using polyethyleneglycol (PEG 1500) (Sigma).</p>
				<p>Hybridomas were grown in DMEM culture medium (Sigma) containing 20% fetal calf serum (FCS) (Seromed, Germany), penicillin (100 <italic>IU/ml</italic>) and streptomycin (100&#xB5;<italic>g/ml</italic>) and supplemented with hypoxantine (1&#x00D7;10<sup>&#x2212;4</sup>
					<italic>M</italic>), aminopterin (4&#x00D7;10<sup>&#x2212;7</sup>
					<italic>M</italic>) and thymidine (1.6&#x00D7;10<sup>&#x2212;5</sup>
					<italic>M</italic>) (HAT) (Sigma). Ten to 14 days after fusion, secreting hybrids were identified by ELISA analysis of culture supernatants as described below. Selected antibody producing cultures were cloned by limiting dilution process according to the conventional methods (<xref ref-type="bibr" rid="CIT0018">18</xref>). Clones secreting antibody of desired reactivity were expanded in 25 and 75 <italic>cm</italic>
					<sup>
						<italic>2</italic>
					</sup> flasks (Nunc, Denmark), harvested and cryo-preserved in 40% fetal calf serum (FCS), 50% RPMI medium and 10% dimethylsulfoxide (DMSO) (Sigma).</p>
			</sec>
			<sec id="S20006">
				<title>Analysis of specificity of MAbs by indirect ELISA</title>
				<p>Microtiter polystyrene plates (Maxisorp, Nunc, Denmark) were coated with 1&#x2013;10 &#xB5;<italic>g/ml</italic> of purified myeloma IgG subclasses or polyclonal IgG in PBS (0.15 <italic>M</italic>, pH=7.2). Then 0.05 <italic>ml</italic> of culture supernatant was added. Appropriate dilution of HRP-conjugated sheep antimouse Ig (prepared in our lab) was subsequently added and the reaction revealed with O-phenylenediamine dihydro-chloride (OPD) (Sigma) substrate. Finally, the reaction was stopped with 20% H2SO4 and the optical density (OD) measured by a multiscan ELISA reader (Organon Teknika, Boxtel, Belgium) at 492<italic>nm</italic>.</p>
			</sec>
			<sec id="S20007">
				<title>Isotype determination of MAbs by capture ELISA</title>
				<p>Goat antimouse IgG1, IgG2a, IgG2b, IgG3, IgA and IgM (Sigma) at 1/1000 dilution, were adsorbed on to the wells of a microtitre ELISA plate (Nunc). Isotype of MAbs in culture supernatants was determined according to the ELISA technique mentioned above.</p>
			</sec>
			<sec id="S20008">
				<title>Affinity constant determination by ELISA</title>
				<p>We determined the affinity constant (K<sub>aff</sub>) by ELISA technique as described elsewhere (<xref ref-type="bibr" rid="CIT0019">19</xref>). Briefly, ELISA plates (Nunc) precoated with three different concentrations of human IgA2 ([Ag], [Ag&#x2032;] and [Ag&#x2032;&#x2032;]) were separately incubated with serial concentrations of each MAb. Sigmoid curves were constructed using the OD values obtained for different concentrations of each MAb. Three non-overlapping curves were selected for each MAb to calculate the affinity constant. The half maximum OD (OD-50) was assigned for all selected curves from which the corresponding antibody concentrations (Ab, Ab&#x2032;, Ab&#x2032;&#x2032;) were extrapolated. Accordingly, Ab and Ab&#x2032; are the measurable total Ab concentrations at OD-50 and OD&#x2032;-50 for plates coated with Ag and Ag&#x0027;, respectively. The affinity constant was determined using the following equation (<xref ref-type="bibr" rid="CIT0020">20</xref>):<disp-formula id="UFD1">
						<mml:math id="UM1">
							<mml:mrow>
								<mml:mtext>Kaff</mml:mtext>
								<mml:mo>=(</mml:mo>
								<mml:mtext>n</mml:mtext>
								<mml:mo>-</mml:mo>
								<mml:mn>1</mml:mn>
								<mml:mo>)/</mml:mo>
								<mml:mn>2</mml:mn>
								<mml:mo stretchy="false">(</mml:mo>
								<mml:mtext>n</mml:mtext>
								<mml:mo stretchy="false">[</mml:mo>
								<mml:mtext>Ab&#x2032;</mml:mtext>
								<mml:mo>]</mml:mo>
								<mml:mtext>t</mml:mtext>
								<mml:mo>-</mml:mo>
								<mml:mo stretchy="false">[</mml:mo>
								<mml:mtext>Ab</mml:mtext>
								<mml:mo stretchy="false">]</mml:mo>
								<mml:mtext>t</mml:mtext>
								<mml:mo stretchy="false">)</mml:mo>
								<mml:mtext>where n</mml:mtext>
								<mml:mo>=</mml:mo>
								<mml:mo stretchy="false">[</mml:mo>
								<mml:mtext>Ag</mml:mtext>
								<mml:mo stretchy="false">]/</mml:mo>
								<mml:mo stretchy="false">[</mml:mo>
								<mml:mtext>Ag&#x2032;</mml:mtext>
								<mml:mo>].</mml:mo>
							</mml:mrow>
						</mml:math>
						<graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="AJMB-1-19-ueq1.tif" alternate-form-of="UFD1"/>
					</disp-formula>
				</p>
			</sec>
			<sec id="S20009">
				<title>Immunoblot analysis of MAbs</title>
				<p>Specificity of MAb was assessed by Immunoblotting technique as described elsewere (<xref ref-type="bibr" rid="CIT0021">21</xref>). Briefly, affinity purified myeloma IgG subclasses, polyclonal IgG and their fragments were electrophoresed under native and denaturing conditions, in 10% polyacryl-amide gel (SDS-PAGE) (Sigma) and then transferred to a nitrocellulose membrane (Schleicher &#x0026; Schuell, Germany).</p>
				<p>After blocking with 2.5% skim milk (Merck, Germany), the membrane was incubated with culture supernatants containing MAbs for 1.5 <italic>hours</italic> at 37<italic>&#x00B0;C</italic>, followed by HRP-conjugated sheep antimouse Ig. The bands were finally visualized with diamino-benzidine tetrahydrochloride (DAB) (Sigma) substrate.</p>
			</sec>
		</sec>
		<sec id="S0010" sec-type="results">
			<title>Results</title>
			<sec id="S20011">
				<title>Screening and selection of specific hybridomas</title>
				<p>Culture supernatants from growing hybridomas were screened by ELISA using a panel of four IgG myelomas with different subclasses, including the immunogen (heavy chain of IgG3). Representative results obtained for a number of hybridomas with different specificity profiles, including the parental 1F18G7 and 1F18A11 hybridomas are illustrated in <xref ref-type="table" rid="T0001">Table 1</xref>.
</p>
				<table-wrap id="T0001">
				<label>Table 1</label>
					<caption>
						<p>Reactivity of representative hybridomas with selected IgG subclasses</p>
					</caption>
					<table frame="hsides" rules="groups">
						<thead>
							<tr>
								<th align="left" rowspan="5" valign="middle">Hybridoma</th>
								<th align="center" colspan="4">Screening Antigen</th>
							</tr>
							<tr>
								<th colspan="4">
									<hr/>
								</th>
							</tr>
							<tr>
								<th align="center" colspan="4">OD (492 <italic>nm</italic>)</th>
							</tr>
							<tr>
								<th colspan="4">
									<hr/>
								</th>
							</tr>
							<tr>
								<th align="center">IgG1(MM13)</th>
								<th align="center">IgG2(MM12)</th>
								<th align="center">IgG3(MM98)</th>
								<th align="center">IgG4(MM147)</th>
							</tr>
						</thead>
						<tbody>
							<tr>
								<td align="left">
									<bold>3F2D8</bold></td>
								<td align="center">1.5</td>
								<td align="center">1.6</td>
								<td align="center">1.9</td>
								<td align="center">1.6</td>
							</tr>
							<tr>
								<td align="left">
									<bold>6F11E1</bold></td>
								<td align="center">1.1</td>
								<td align="center">1.2</td>
								<td align="center">0.2</td>
								<td align="center">1.3</td>
							</tr>
							<tr>
								<td align="left">
									<bold>1F18G7</bold></td>
								<td align="center">0.1</td>
								<td align="center">0.2</td>
								<td align="center">1.6</td>
								<td align="center">0.2</td>
							</tr>
							<tr>
								<td align="left">
									<bold>1F18A8</bold></td>
								<td align="center">0.15</td>
								<td align="center">0.2</td>
								<td align="center">2</td>
								<td align="center">0.3</td>
							</tr>
							<tr>
								<td align="left">
									<bold>Anti IgG1 (JL512)</bold></td>
								<td align="center">1.2</td>
								<td align="center">0.27</td>
								<td align="center">0.3</td>
								<td align="center">0.27</td>
							</tr>
							<tr>
								<td align="left">
									<bold>Anti IgG2 (GOM2)</bold></td>
								<td align="center">0.4</td>
								<td align="center">2</td>
								<td align="center">0.3</td>
								<td align="center">0.25</td>
							</tr>
							<tr>
								<td align="left">
									<bold>Anti IgG3 (ZG4)</bold></td>
								<td align="center">0.3</td>
								<td align="center">0.3</td>
								<td align="center">1.9</td>
								<td align="center">0.3</td>
							</tr>
							<tr>
								<td align="left">
									<bold>Anti IgG4 (RJ4)</bold></td>
								<td align="center">0.3</td>
								<td align="center">0.3</td>
								<td align="center">0.3</td>
								<td align="center">1.6</td>
							</tr>
						</tbody>
					</table>
				</table-wrap>
			</sec>
			<sec id="S20012">
				<title>Characterization of MAbs</title>
				<p>Following cloning and subcloning, culture supernatant from the selected 1F18G7 and 1F18A11 hybridomas was further characterized. Electrophoresis of ascitic fluids revealed a sharp monoclonal band in the &#x03B3;-globulin region (<xref ref-type="fig" rid="F0001">Figure 1</xref>), belonging to IgG1 isotype (<xref ref-type="table" rid="T0002">Table 2</xref>). Specificity of the MAbs was determined, using a panel of purified myeloma proteins, including IgG1 (n=9), IgG2 (n=4), IgG3 (n=7) and IgG4 (n=7) sub-classes. Our results demonstrated that both MAbs were specific for isotypic epitope (s) restricted to IgG3 subclass (<xref ref-type="fig" rid="F0002">Figure 2</xref>). The MAbs reacted only with Fc, but not Fab fragments of the IgG3 molecule (<xref ref-type="fig" rid="F0003">Figure 3</xref>). Immunoblotting studies demonstrated that both of our MAbs recognize sequential epitopes (<xref ref-type="fig" rid="F0004">Figures 4A</xref> and <xref ref-type="fig" rid="F0005">4B</xref>) located on human IgG3 heavy chain.
</p>
				<fig id="F0001">
					<label>Figure 1</label>
					<caption>
						<p>Acetate cellulose electrophoresis of ascitic fluids of 1 F18G7 and 1F18A8 MAbs. NS=Normal serum; 4F18B12=Anti nG1m (a) isoallotype MAb employed as a control</p>
					</caption>
					<graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="AJMB-1-19-g001.tif" alt-version="no"/>
				</fig>
				<fig id="F0002">
					<label>Figure 2</label>
					<caption>
						<p>Reactivity of IgG3 specific MAbs with IgG subclasses</p><p>Lanes 1 to 28 represent: MM1, MM11, MM24, MM46, MM50, MM53, MM63, MM65, MM13, MM12, G2 (M), MM62, Camp, MM98, Gale, Hay, Pol, Goe, Ren, Mcw, IgG3 polyclonal, MM147, Rea, Jan, Will, Cart, J. Wil, Ze</p>
					</caption>
					<graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="AJMB-1-19-g002.tif" alt-version="no"/>
				</fig>
				<fig id="F0003">
					<label>Figure 3</label>
					<caption>
						<p>Reactivity of IgG3 specific MAbs with enzymatic fragments of MM98 (IgG3). Control represents a mouse MAb (HP6050) with anti-IgG3 specificity</p>
					</caption>
					<graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="AJMB-1-19-g003.tif" alt-version="no"/>
				</fig>
				<fig id="F0004">
					<label>Figure 4A</label>
					<caption>
						<p>Immunoblot analysis of 1F18G7 MAb reactivity with IgG subclasses. Lanes 1 to 5 represent reduced forms of MM1 (IgG1), MM12 (IgG2), Hay-ward (Heavy chain of IgG3), MM98 (IgG3) and MM147 (IgG4), respectively. Lanes 6 to 13 represent non reduced forms of MM1, MM12, Hay-ward, MM98 (whole molecule), MM98 (Fab), MM98 (Fc), IgG3 polyclonal and MM147, respectively.</p>
					</caption>
					<graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="AJMB-1-19-g004.tif" alt-version="no"/>
				</fig>
				<fig id="F0005">
					<label>Figure 4B</label>
					<caption>
						<p>Immunoblot analysis of 1F18A8 reactivity with IgG subclasses. See footnote to <xref ref-type="fig" rid="F0004">figure 4A</xref>.</p>
					</caption>
					<graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="AJMB-1-19-g005.tif" alt-version="no"/>
				</fig>
				<table-wrap id="T0002">
				<label>Table 2</label>
					<caption>
						<p>Determination of the isotype of MAbs by ELISA</p>
					</caption>
					<table frame="hsides" rules="groups">
						<thead>
							<tr>
								<th align="left" rowspan="3" valign="bottom">Isotype</th>
								<th align="center" colspan="3">MAbs</th>
							</tr>
							<tr>
								<th colspan="3">
									<hr/>
								</th>
							</tr>
							<tr>
								<th align="center">1F18G7</th>
								<th align="center">1F18A8</th>
								<th align="center">Control<sup>&#x2212;</sup>
								</th>
							</tr>
						</thead>
						<tbody>
							<tr>
								<td align="left">
									<bold>IgG1</bold></td>
								<td align="center">0.7</td>
								<td align="center">0.8</td>
								<td align="center">0.16</td>
							</tr>
							<tr>
								<td align="left">
									<bold>IgG2a</bold></td>
								<td align="center">0.1</td>
								<td align="center">0.13</td>
								<td align="center">0.14</td>
							</tr>
							<tr>
								<td align="left">
									<bold>IgG2b</bold></td>
								<td align="center">0.12</td>
								<td align="center">0.1</td>
								<td align="center">0.1</td>
							</tr>
							<tr>
								<td align="left">
									<bold>IgG3</bold></td>
								<td align="center">0.1</td>
								<td align="center">0.15</td>
								<td align="center">0.15</td>
							</tr>
							<tr>
								<td align="left">
									<bold>IgA</bold></td>
								<td align="center">0.14</td>
								<td align="center">0.1</td>
								<td align="center">0.1</td>
							</tr>
							<tr>
								<td align="left">
									<bold>IgM</bold></td>
								<td align="center">0.15</td>
								<td align="center">0.1</td>
								<td align="center">0.16</td>
							</tr>
						</tbody>
					</table>
					<table-wrap-foot>
						<fn>
							<p>Control<sup>&#x2212;</sup>. Culture supernatant from SP2/0 myeloma cells</p>
						</fn>
					</table-wrap-foot>
				</table-wrap>
				<p>Cross-reactivity studies employing whole sera from a range of animal species indicate that MAb 1F18A8 shows a weak cross-reactivity with only dog serum (<xref ref-type="table" rid="T0003">Table 3</xref>).
</p>
				<table-wrap id="T0003">
				<label>Table 3</label>
					<caption>
						<p>Cross-reactivity of MAbs with animal sera</p>
					</caption>
					<table frame="hsides" rules="groups">
						<thead>
							<tr>
								<th align="left" rowspan="3" valign="middle">Animal sera</th>
								<th align="center" colspan="2">Cross-reactivity%<xref ref-type="table-fn" rid="TF0001">&#x002A;</xref></th>
							</tr>
							<tr>
								<th colspan="2">
									<hr/>
								</th>
							</tr>
							<tr>
								<th align="center">1F18G7</th>
								<th align="center">1F18A8</th>
							</tr>
						</thead>
						<tbody>
							<tr>
								<td align="left">
									<bold>Monkey</bold></td>
								<td align="center">&#x003C;0.1</td>
								<td align="center">&#x003C;0.1</td>
							</tr>
							<tr>
								<td align="left">
									<bold>Rabbit</bold></td>
								<td align="center">&#x003C;0.1</td>
								<td align="center">&#x003C;0.1</td>
							</tr>
							<tr>
								<td align="left">
									<bold>Guinea Pig</bold></td>
								<td align="center">&#x003C;0.1</td>
								<td align="center">&#x003C;0.1</td>
							</tr>
							<tr>
								<td align="left">
									<bold>Sheep</bold></td>
								<td align="center">&#x003C;0.1</td>
								<td align="center">&#x003C;0.1</td>
							</tr>
							<tr>
								<td align="left">
									<bold>Goat</bold></td>
								<td align="center">&#x003C;0.1</td>
								<td align="center">&#x003C;0.1</td>
							</tr>
							<tr>
								<td align="left">
									<bold>Cat</bold></td>
								<td align="center">&#x003C;0.1</td>
								<td align="center">&#x003C;0.1</td>
							</tr>
							<tr>
								<td align="left">
									<bold>Dog</bold></td>
								<td align="center">&#x003C;0.1</td>
								<td align="center">8</td>
							</tr>
							<tr>
								<td align="left">
									<bold>Horse</bold></td>
								<td align="center">&#x003C;0.1</td>
								<td align="center">&#x003C;0.1</td>
							</tr>
							<tr>
								<td align="left">
									<bold>Hen</bold></td>
								<td align="center">&#x003C;0.1</td>
								<td align="center">&#x003C;0.1</td>
							</tr>
						</tbody>
					</table>
					<table-wrap-foot>
						<fn id="TF0001">
						<label>&#x002A;</label>
							<p>% Cross-reactivity is expressed relative to the value obtained for human pooled serum.</p>
						</fn>
					</table-wrap-foot>
				</table-wrap>
			</sec>
			<sec id="S20013">
				<title>Determination of affinity of MAbs</title>
				<p>The ascitic fluids of our MAbs were purified by affinity chromatography using Streptococcal protein G column and the affinity constant (K<sub>aff</sub>) was determined by ELISA. Triple serial concentrations of the antigen (IgG3) and MAbs were selected to construct the corresponding curves and extrapolate the K<sub>aff</sub> values using the formula given in materials and methods. Representative curves obtained for the MAbs are illustrated in <xref ref-type="fig" rid="F0006">Figure 5</xref> and the calculated average K<sub>aff</sub> values are presented in <xref ref-type="table" rid="T0004">Table 4</xref>.
</p>
				<fig id="F0006">
					<label>Figure 5A</label>
					<caption>
						<p>Representative binding curves employed for extrapolation of affinity constant of 1F18G7 MAb.</p>
					</caption>
					<graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="AJMB-1-19-g006.tif" alt-version="no"/>
				</fig>
				<fig id="F0007">
					<label>Figure 5B</label>
					<caption>
						<p>Representative binding curves employed for extrapolation of affinity constant of 1F18A8 MAb.</p>
					</caption>
					<graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="AJMB-1-19-g007.tif" alt-version="no"/>
				</fig>
				<table-wrap id="T0004">
				<label>Table 4</label>
					<caption>
						<p>Affinity constants of h-IgG3 specific MAbs determined by ELISA</p>
					</caption>
					<table frame="hsides" rules="groups">
						<thead>
							<tr>
								<th align="left">MAbs</th>
								<th align="center">Ag (ng/ml)</th>
								<th align="center">OD-50<xref ref-type="table-fn" rid="TF0002">&#x002A;</xref></th>
								<th align="center">Ab at OD-50 (ng/ml)</th>
								<th align="center">Kaff (M<sup>&#x2212;1</sup>)</th>
								<th align="center">Average Kaff (M<sup>&#x2212;1</sup>)&#x00B1;SD</th>
							</tr>
						</thead>
						<tbody>
							<tr>
								<td colspan="6" align="left">
									<bold>1F18G7</bold></td>
							</tr>
							<tr>
							<td align="left" rowspan="3"/>
								<td align="center">250</td>
								<td align="center">0.99</td>
								<td align="center">79</td>
								<td align="center">0.9&#x00D7;10<sup>9</sup>
								</td>
								<td align="center" rowspan="3" valign="middle">0.81&#x00D7;10<sup>9</sup>
								</td>
							</tr>
							<tr>
								<td align="center">125</td>
								<td align="center">0.9</td>
								<td align="center">81</td>
								<td align="center">0.74&#x00D7;10<sup>9</sup>
								</td>
							</tr>
							<tr>
								<td align="center">62.5</td>
								<td align="center">0.8</td>
								<td align="center">91</td>
								<td align="center">0.79&#x00D7;10<sup>9</sup>
								</td>
							</tr>
							<tr>
								<td colspan="6" align="left">
									<bold>1F18A8</bold></td>
							</tr>
							<tr>
							<td align="left" rowspan="3"/>
								<td align="center">250</td>
								<td align="center">0.9</td>
								<td align="center">93</td>
								<td align="center">0.7&#x00D7;10<sup>9</sup>
								</td>
								<td align="center" rowspan="3" valign="middle">0.71&#x00D7;10<sup>9</sup>
								</td>
							</tr>
							<tr>
								<td align="center">125</td>
								<td align="center">0.84</td>
								<td align="center">100</td>
								<td align="center">0.71&#x00D7;10<sup>9</sup>
								</td>
							</tr>
							<tr>
								<td align="center">62.5</td>
								<td align="center">0.69</td>
								<td align="center">103</td>
								<td align="center">0.71&#x00D7;10<sup>9</sup>
								</td>
							</tr>
						</tbody>
					</table>
					<table-wrap-foot>
						<fn id="TF0002">
						<label>&#x002A;</label>
							<p>OD-50 represents the half maximum optical density obtained for a given concentration of h-IgG3 heavy chain ([Ag]) and the corresponding MAb ([Ab]). The affinity constant (<italic>K</italic>
								<sub>
									<italic>aff</italic>
								</sub>) for each selected concentration of Ag and Ab was determined using the formula described in the Materials and Methods.</p>
						</fn>
					</table-wrap-foot>
				</table-wrap>
			</sec>
		</sec>
		<sec id="S0014" sec-type="discussion">
			<title>Discussion</title>
			<p>In the present study we produced and characterized two murine MAbs specific for human IgG3 subclass. These MAbs were selected among a large collection of MAbs recognizing different epitopes located on human IgG subclasses. Several MAbs specific to human IgG3 subclass have been produced by other investigators (<xref ref-type="bibr" rid="CIT0022">22</xref>&#x2013;<xref ref-type="bibr" rid="CIT0025">25</xref>).</p>
			<p>These MAbs were shown to be specific for isotypic epitopes of IgG3 subclass, including: B12A8 specific for IgG3 (<xref ref-type="bibr" rid="CIT0025">25</xref>); HP6047 (<xref ref-type="bibr" rid="CIT0022">22</xref>, <xref ref-type="bibr" rid="CIT0026">26</xref>), HP6050 (<xref ref-type="bibr" rid="CIT0022">22</xref>, <xref ref-type="bibr" rid="CIT0023">23</xref>, <xref ref-type="bibr" rid="CIT0026">26</xref>), HP6010, MYSJ33 (<xref ref-type="bibr" rid="CIT0022">22</xref>, <xref ref-type="bibr" rid="CIT0023">23</xref>), BRL1211 (<xref ref-type="bibr" rid="CIT0022">22</xref>), HP6048 and HP6066 (<xref ref-type="bibr" rid="CIT0023">23</xref>), with specificity for hinge region; HP6003, HP6004 (<xref ref-type="bibr" rid="CIT0022">22</xref>, <xref ref-type="bibr" rid="CIT0023">23</xref>), HP6005 (<xref ref-type="bibr" rid="CIT0023">23</xref>) and HP60193 (<xref ref-type="bibr" rid="CIT0024">24</xref>) with specificity for Fc region and HP6201 (<xref ref-type="bibr" rid="CIT0024">24</xref>) specific for F(ab&#x0027;)2 fragments. All the above anti IgG3 MAbs, except MYSJ33 and HP6076 belonged to IgG1 subclass (like our MAbs). MYSJ33 and HP6076 MAbs belonged to IgM and IgG2b isotypes, respectively. The specificity of these MAbs was evaluated with a wide range of assay protocols (<xref ref-type="bibr" rid="CIT0023">23</xref>, <xref ref-type="bibr" rid="CIT0024">24</xref>).</p>
			<p>A panel of WHO specificity reference reagents (SRR) for IgG subclasses was established (<xref ref-type="bibr" rid="CIT0027">27</xref>). In the above studies purified IgG3 paraproteins (<xref ref-type="bibr" rid="CIT0022">22</xref>&#x2013;<xref ref-type="bibr" rid="CIT0024">24</xref>) or IgG Fc region obtained from human plasma (<xref ref-type="bibr" rid="CIT0025">25</xref>), were used for immunization of Balb/C mice while we used a heavy chain of an IgG3 myeloma for immunization.</p>
			<p>Thus our IgG3 specific MAbs can be seen useful tools for diagnosis of &#x03B3;<sub>3-</sub>heavy chain diseases as well. In addition we also determined the specificity of our MAbs by immunoblotting under reduced and non-reduced conditions and determined the nature of their epitopes. The most reliable IgG3 specific MAbs produced by other investigators are HP6048, HP6050 and HP6066 which recognize epitopes localized in the hinge region. This specificity may preclude or complicate their application in some conditions; since it has previously been demonstrated that reduction of disulfide bridges in the hinge region destroys these epitopes (<xref ref-type="bibr" rid="CIT0023">23</xref>).</p>
			<p>Our MAbs, however, recognize linear epitopes on IgG3 heavy chains (under reduced conditions) suggesting stability of the corresponding epitope (s) and their applicability as suitable tools in different assay conditions. IgG3 subclass differs from other subclasses in hinge region and also in amino acid sequences at positions 276 and 291 in CH2 domain and positions 392, 422 and 435 in CH3 domain. In IgG1, 2 and 4 subclasses, these amino acids are Asn, Pro, Lys, Val and His, whereas in IgG3 subclass they include Lys, Ile and Arg, respectively (<xref ref-type="bibr" rid="CIT0028">28</xref>). It seems that our MAbs recognize epitope(s) located in the CH2 or CH3 domain of human IgG3 subclass. The affinity constant (K<sub>aff</sub>) of some IgG3 specific MAbs have been determined previously (<xref ref-type="bibr" rid="CIT0024">24</xref>, <xref ref-type="bibr" rid="CIT0029">29</xref>).</p>
			<p>The K<sub>aff</sub> of HP6003 and HP6004 (anti-IgG3 Fc), HP6010, HP6047 and HP6050 (anti-IgG3 hinge) has been determined by fluorescent sequential&#x2013;saturation assay (<xref ref-type="bibr" rid="CIT0029">29</xref>) and found to be 2.7&#x00D7;10<sup>7</sup>, 2.5&#x00D7;10<sup>7</sup>, 6.5&#x00D7;10<sup>7</sup>, 3.9&#x00D7;10<sup>7</sup> and 5&#x00D7;10<sup>7</sup>
				<italic>Mol</italic>
				<sup>
					<italic>&#x2212;1</italic>
				</sup>, respectively. Immunoprecipitation studies have estimated higher avidity for HP60193, HP60194, HP6201, HP6050 and HP60195 MAbs (<xref ref-type="bibr" rid="CIT0029">29</xref>).</p>
			<p>Application of different methodologies for affinity determination may explain this discrepancy in part. We measured the affinity constant of our MAbs by an ELISA-based method. The affinity constant of both of our MAbs was found in the order of 10<sup>8</sup>	<italic>Mol</italic>
				<sup>
					<italic>&#x2212;1</italic>
				</sup> (<xref ref-type="table" rid="T0004">Table 4</xref>) which is much higher than many of the previously reported IgG3-specific MAbs.</p>
			<p>One of our MAbs (1F18A8) showed a weak cross reactivity with dog serum. To the best of our knowledge this is the first report on the cross reactivity of a human IgG3 specific MAb with an animal serum. Canine IgG is composed of four subclasses which are defined as IgG1, IgG2, IgG3 and IgG4 (<xref ref-type="bibr" rid="CIT0030">30</xref>, <xref ref-type="bibr" rid="CIT0031">31</xref>). Thus weak cross-reactivity of our MAb with dog serum, may suggest reactivity with dog IgG3.</p>
			<p>Our MAbs with relatively high affinity for recognizing linear epitopes on IgG3 Fc could be used as suitable tools for quantification of IgG3 subclass in different clinical conditions and also be applied for epitope mapping of the human IgG3 subclass and its structural-functional analysis.</p>
		</sec>
	</body>
	<back>
		<ack>
			<title>Acknowledgement</title>
			<p>We are grateful to Mahmood Jeddi-Tehrani, Soheila Gharagozlou, Roya Ghods, Jalal Khoshnoodi and Azam Roohi for scientific consultations and preparation of the anti-gens. This study was supported in part by a grant from the Research and Technology Undersecretary of the Ministry of Health, Treatment and Medical Education of Iran.</p>
		</ack>
		<ref-list>
			<title>References</title>
			<ref id="CIT0001">
				<label>1</label>
				<nlm-citation citation-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Stanisic</surname>
							<given-names>DI</given-names>
						</name>
						<name>
							<surname>Richards</surname>
							<given-names>JS</given-names>
						</name>
						<name>
							<surname>McCallum</surname>
							<given-names>FJ</given-names>
						</name>
						<name>
							<surname>Michon</surname>
							<given-names>P</given-names>
						</name>
						<name>
							<surname>King</surname>
							<given-names>CL</given-names>
						</name>
						<name>
							<surname>Schoepflin</surname>
							<given-names>S</given-names>
						</name>
					</person-group>
					<article-title>IgG subclassspecific responses against Plasmodium falciparum merozoite antigens are associated with control of parasitemia and protection from symptomatic illness</article-title>
					<source>Infect Immun</source>
					<year>2009</year>
					<volume>77</volume>
					<issue>3</issue>
					<fpage>1165</fpage>
					<lpage>1174</lpage>
				</nlm-citation>
			</ref>
			<ref id="CIT0002">
				<label>2</label>
				<nlm-citation citation-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Murphy</surname>
							<given-names>SL</given-names>
						</name>
						<name>
							<surname>Li</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Mingozzi</surname>
							<given-names>F</given-names>
						</name>
						<name>
							<surname>Sabatino</surname>
							<given-names>DE</given-names>
						</name>
						<name>
							<surname>Hui</surname>
							<given-names>DJ</given-names>
						</name>
						<name>
							<surname>Edmonson</surname>
							<given-names>SA</given-names>
						</name>
					</person-group>
					<article-title>Diverse IgG subclass responses to adeno-associated virus infection and vector administration</article-title>
					<source>J Med Virol</source>
					<year>2009</year>
					<volume>81</volume>
					<issue>1</issue>
					<fpage>65</fpage>
					<lpage>74</lpage>
				</nlm-citation>
			</ref>
			<ref id="CIT0003">
				<label>3</label>
				<nlm-citation citation-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Candore</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Campagna</surname>
							<given-names>AM</given-names>
						</name>
						<name>
							<surname>Cuppari</surname>
							<given-names>I</given-names>
						</name>
						<name>
							<surname>Di Carlo</surname>
							<given-names>D</given-names>
						</name>
						<name>
							<surname>Mineo</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Caruso</surname>
							<given-names>C</given-names>
						</name>
					</person-group>
					<article-title>Genetic control of immune response in carriers of the 8.1 ancestral haplotype: correlation with levels of IgG subclasses: its relevance in the pathogenesis of autoimmune diseases</article-title>
					<source>Ann N Y Acad Sci</source>
					<year>2007</year>
					<volume>1110</volume>
					<fpage>151</fpage>
					<lpage>158</lpage>
				</nlm-citation>
			</ref>
			<ref id="CIT0004">
				<label>4</label>
				<nlm-citation citation-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Towfighi</surname>
							<given-names>F</given-names>
						</name>
						<name>
							<surname>Gharagozlou</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Sharifian</surname>
							<given-names>RA</given-names>
						</name>
						<name>
							<surname>Kazemnejad</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Esmailzadeh</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Managhchi</surname>
							<given-names>MR</given-names>
						</name>
					</person-group>
					<article-title>Comparative measurement of anti factor VIII antibody by Bethesda assay and ELISA reveals restricted isotype profile and epitope specificity</article-title>
					<source>Acta Haematol</source>
					<year>2005</year>
					<volume>114</volume>
					<issue>2</issue>
					<fpage>84</fpage>
					<lpage>90</lpage>
				</nlm-citation>
			</ref>
			<ref id="CIT0005">
				<label>5</label>
				<nlm-citation citation-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Izad</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Jefferis</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Shokri</surname>
							<given-names>F</given-names>
						</name>
					</person-group>
					<article-title>IgG subclass analysis of affinity purified anti-HBs antibodies isolated from normal individuals vaccinated with recombinant HBsAg or naturally infected with hepatitis B virus</article-title>
					<source>Ir J Med Sci</source>
					<year>2000</year>
					<volume>25</volume>
					<fpage>42</fpage>
					<lpage>49</lpage>
				</nlm-citation>
			</ref>
			<ref id="CIT0006">
				<label>6</label>
				<nlm-citation citation-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Shokrgozar</surname>
							<given-names>MA</given-names>
						</name>
						<name>
							<surname>Shokri</surname>
							<given-names>F</given-names>
						</name>
					</person-group>
					<article-title>Subtype specificity of anti-HBs antibodies produced by human B-cell lines isolated from normal individuals vaccinated with recombinant hepatitis B vaccine</article-title>
					<source>Vaccine</source>
					<year>2002</year>
					<volume>20</volume>
					<issue>17-18</issue>
					<fpage>2215</fpage>
					<lpage>2220</lpage>
				</nlm-citation>
			</ref>
			<ref id="CIT0007">
				<label>7</label>
				<nlm-citation citation-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Pasha</surname>
							<given-names>RP</given-names>
						</name>
						<name>
							<surname>Bahrami</surname>
							<given-names>ZS</given-names>
						</name>
						<name>
							<surname>Niroomanesh</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Ramzi</surname>
							<given-names>F</given-names>
						</name>
						<name>
							<surname>Razavi</surname>
							<given-names>AR</given-names>
						</name>
						<name>
							<surname>Shokri</surname>
							<given-names>F</given-names>
						</name>
					</person-group>
					<article-title>Specificity and isotype of Rh specific antibodies produced by human B-cell lines established from alloimmunized Rh negative women</article-title>
					<source>Transfus Apher Sci</source>
					<year>2005</year>
					<volume>33</volume>
					<issue>2</issue>
					<fpage>119</fpage>
					<lpage>127</lpage>
				</nlm-citation>
			</ref>
			<ref id="CIT0008">
				<label>8</label>
				<nlm-citation citation-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Wu</surname>
							<given-names>Q</given-names>
						</name>
						<name>
							<surname>Zhang</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Liu</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Wang</surname>
							<given-names>B</given-names>
						</name>
						<name>
							<surname>Liu</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>He</surname>
							<given-names>C</given-names>
						</name>
					</person-group>
					<article-title>Correlation of FcgammaRIIa (CD32) Polymor-phism and IgG antibody subclasses in hemolytic disease of newborn</article-title>
					<source>Neonatology</source>
					<year>2009</year>
					<volume>96</volume>
					<issue>1</issue>
					<fpage>1</fpage>
					<lpage>5</lpage>
				</nlm-citation>
			</ref>
			<ref id="CIT0009">
				<label>9</label>
				<nlm-citation citation-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Windle</surname>
							<given-names>HJ</given-names>
						</name>
						<name>
							<surname>Ang</surname>
							<given-names>YS</given-names>
						</name>
						<name>
							<surname>Athie-Morales</surname>
							<given-names>V</given-names>
						</name>
						<name>
							<surname>McManus</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Kelleher</surname>
							<given-names>D</given-names>
						</name>
					</person-group>
					<article-title>Human peripheral and gastric lymphocyte responses to Helicobacter pylori NapA and AphC differ in infected and uninfected individuals</article-title>
					<source>Gut</source>
					<year>2005</year>
					<volume>54</volume>
					<issue>1</issue>
					<fpage>25</fpage>
					<lpage>32</lpage>
				</nlm-citation>
			</ref>
			<ref id="CIT0010">
				<label>10</label>
				<nlm-citation citation-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Morais</surname>
							<given-names>CG</given-names>
						</name>
						<name>
							<surname>Soares</surname>
							<given-names>IS</given-names>
						</name>
						<name>
							<surname>Carvalho</surname>
							<given-names>LH</given-names>
						</name>
						<name>
							<surname>Fontes</surname>
							<given-names>CJ</given-names>
						</name>
						<name>
							<surname>Krettli</surname>
							<given-names>AU</given-names>
						</name>
						<name>
							<surname>Braga</surname>
							<given-names>EM</given-names>
						</name>
					</person-group>
					<article-title>IgG isotype to C terminal 19 kD of Plasmodium vivax merozoite surface protein 1 among subjects with different levels of exposure to malaria in Brazil</article-title>
					<source>Parasitol Res</source>
					<year>2005</year>
					<volume>95</volume>
					<issue>6</issue>
					<fpage>420</fpage>
					<lpage>426</lpage>
				</nlm-citation>
			</ref>
			<ref id="CIT0011">
				<label>11</label>
				<nlm-citation citation-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Burton</surname>
							<given-names>DR</given-names>
						</name>
						<name>
							<surname>Gregory</surname>
							<given-names>L</given-names>
						</name>
						<name>
							<surname>Jefferis</surname>
							<given-names>R</given-names>
						</name>
					</person-group>
					<article-title>Aspects of the molecular structure of IgG subclasses</article-title>
					<source>Monogr Allergy</source>
					<year>1986</year>
					<volume>19</volume>
					<fpage>7</fpage>
					<lpage>35</lpage>
				</nlm-citation>
			</ref>
			<ref id="CIT0012">
				<label>12</label>
				<nlm-citation citation-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Van de Winkel</surname>
							<given-names>JG</given-names>
						</name>
						<name>
							<surname>Anderson</surname>
							<given-names>CL</given-names>
						</name>
					</person-group>
					<article-title>Biology of human immunoglobulin G Fc receptors</article-title>
					<source>J Leukoc Biol</source>
					<year>1991</year>
					<volume>49</volume>
					<issue>5</issue>
					<fpage>511</fpage>
					<lpage>524</lpage>
				</nlm-citation>
			</ref>
			<ref id="CIT0013">
				<label>13</label>
				<nlm-citation citation-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Xu</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Oomen</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Klein</surname>
							<given-names>MH</given-names>
						</name>
					</person-group>
					<article-title>Residue at position 331 in the IgG1 and IgG4 CH2 domains contributes to their differential ability to bind and activate complement</article-title>
					<source>J Biol Chem</source>
					<year>1994</year>
					<volume>269</volume>
					<issue>5</issue>
					<fpage>3469</fpage>
					<lpage>3474</lpage>
				</nlm-citation>
			</ref>
			<ref id="CIT0014">
				<label>14</label>
				<nlm-citation citation-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Brekke</surname>
							<given-names>OH</given-names>
						</name>
						<name>
							<surname>Michaelsen</surname>
							<given-names>TE</given-names>
						</name>
						<name>
							<surname>Sandlie</surname>
							<given-names>I</given-names>
						</name>
					</person-group>
					<article-title>The structural requirements for complement activation by IgG: does it hinge on the hinge?</article-title>
					<source>Immunol Today</source>
					<year>1995</year>
					<volume>16</volume>
					<issue>2</issue>
					<fpage>85</fpage>
					<lpage>90</lpage>
				</nlm-citation>
			</ref>
			<ref id="CIT0015">
				<label>15</label>
				<nlm-citation citation-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Lu</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Harding</surname>
							<given-names>SE</given-names>
						</name>
						<name>
							<surname>Michaelsen</surname>
							<given-names>TE</given-names>
						</name>
						<name>
							<surname>Longman</surname>
							<given-names>E</given-names>
						</name>
						<name>
							<surname>Davis</surname>
							<given-names>KG</given-names>
						</name>
						<name>
							<surname>Ortega</surname>
							<given-names>A</given-names>
						</name>
					</person-group>
					<article-title>Solution conformation of wild-type and mutant IgG3 and IgG4 immuno-globulins using crystallohydrodynamics: possible implications for complement activation</article-title>
					<source>Biophys J</source>
					<year>2007</year>
					<volume>93</volume>
					<issue>11</issue>
					<fpage>3733</fpage>
					<lpage>3744</lpage>
				</nlm-citation>
			</ref>
			<ref id="CIT0016">
				<label>16</label>
				<nlm-citation citation-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>McLean</surname>
							<given-names>GR</given-names>
						</name>
						<name>
							<surname>Torres</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Trotter</surname>
							<given-names>B</given-names>
						</name>
						<name>
							<surname>Noseda</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Bryson</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Pai</surname>
							<given-names>EF</given-names>
						</name>
					</person-group>
					<article-title>A point mutation in the Ch3 domain of human IgG3 inhibits antibody secre-tion without affecting antigen specificity</article-title>
					<source>Mol Immunol</source>
					<year>2005</year>
					<volume>42</volume>
					<issue>9</issue>
					<fpage>1111</fpage>
					<lpage>1119</lpage>
				</nlm-citation>
			</ref>
			<ref id="CIT0017">
				<label>17</label>
				<nlm-citation citation-type="book">
					<person-group person-group-type="author">
						<name>
							<surname>Edelman</surname>
							<given-names>GM</given-names>
						</name>
						<name>
							<surname>Marchalonis</surname>
							<given-names>JJ</given-names>
						</name>
					</person-group>
					<person-group person-group-type="editor">
						<name>
							<surname>Williams</surname>
							<given-names>CH</given-names>
						</name>
						<name>
							<surname>Chase</surname>
							<given-names>MW</given-names>
						</name>
					</person-group>
					<article-title>Methods used in studies of the structure of immunoglobulins</article-title>
					<source>Methods of Immunology and Immunochemistry</source>
					<year>1967</year>
					<publisher-loc>New York</publisher-loc>
					<publisher-name>Academic Press</publisher-name>
					<fpage>405</fpage>
					<lpage>424</lpage>
				</nlm-citation>
			</ref>
			<ref id="CIT0018">
				<label>18</label>
				<nlm-citation citation-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Loirat</surname>
							<given-names>MJ</given-names>
						</name>
						<name>
							<surname>Gourbil</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Frioux</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Muller</surname>
							<given-names>JY</given-names>
						</name>
						<name>
							<surname>Blanchard</surname>
							<given-names>D</given-names>
						</name>
					</person-group>
					<article-title>A murine monoclonal antibody directed against the Gerbich 3 blood group antigen</article-title>
					<source>Vox Sang</source>
					<year>1992</year>
					<volume>62</volume>
					<issue>1</issue>
					<fpage>45</fpage>
					<lpage>48</lpage>
				</nlm-citation>
			</ref>
			<ref id="CIT0019">
				<label>19</label>
				<nlm-citation citation-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Hajighasemi</surname>
							<given-names>F</given-names>
						</name>
						<name>
							<surname>Saboor-Yaraghi</surname>
							<given-names>AA</given-names>
						</name>
						<name>
							<surname>Shokri</surname>
							<given-names>F</given-names>
						</name>
					</person-group>
					<article-title>Measurement of affinity constant of antihuman IgG monoclonal antibodies by an Elisa based method</article-title>
					<source>Iranian J Immunol</source>
					<year>2004</year>
					<volume>1</volume>
					<issue>3</issue>
					<fpage>154</fpage>
					<lpage>161</lpage>
				</nlm-citation>
			</ref>
			<ref id="CIT0020">
				<label>20</label>
				<nlm-citation citation-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Beatty</surname>
							<given-names>JD</given-names>
						</name>
						<name>
							<surname>Beatty</surname>
							<given-names>BG</given-names>
						</name>
						<name>
							<surname>Vlahos</surname>
							<given-names>WG</given-names>
						</name>
					</person-group>
					<article-title>Measurement of monoclonal antibody affinity by non-competi-tive enzyme immunoassay</article-title>
					<source>J Immunol Meth</source>
					<year>1987</year>
					<volume>100</volume>
					<issue>1-2</issue>
					<fpage>173</fpage>
					<lpage>179</lpage>
				</nlm-citation>
			</ref>
			<ref id="CIT0021">
				<label>21</label>
				<nlm-citation citation-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Hadji-Ghasemi</surname>
							<given-names>F</given-names>
						</name>
						<name>
							<surname>Gharagozlou</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Ghods</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Roohi</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Khoshnoodi</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Shokri</surname>
							<given-names>F</given-names>
						</name>
					</person-group>
					<article-title>Generation and characterization of a mouse monoclonal antibody with specificity similar to staphylococcal protein A (SPA)</article-title>
					<source>Hybrid Hybridomics</source>
					<year>2003</year>
					<volume>22</volume>
					<issue>1</issue>
					<fpage>33</fpage>
					<lpage>39</lpage>
				</nlm-citation>
			</ref>
			<ref id="CIT0022">
				<label>22</label>
				<nlm-citation citation-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Reimer</surname>
							<given-names>CB</given-names>
						</name>
						<name>
							<surname>Phillips</surname>
							<given-names>DJ</given-names>
						</name>
						<name>
							<surname>Aloisio</surname>
							<given-names>CH</given-names>
						</name>
						<name>
							<surname>Moore</surname>
							<given-names>DD</given-names>
						</name>
						<name>
							<surname>Galland</surname>
							<given-names>GG</given-names>
						</name>
						<name>
							<surname>Wells</surname>
							<given-names>TW</given-names>
						</name>
					</person-group>
					<article-title>Evaluation of thirty one mouse monoclonal antibodies to human IgG epitopes</article-title>
					<source>Hybridoma</source>
					<year>1984</year>
					<volume>3</volume>
					<issue>3</issue>
					<fpage>263</fpage>
					<lpage>275</lpage>
				</nlm-citation>
			</ref>
			<ref id="CIT0023">
				<label>23</label>
				<nlm-citation citation-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Jefferis</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Reimer</surname>
							<given-names>CB</given-names>
						</name>
						<name>
							<surname>Skvaril</surname>
							<given-names>F</given-names>
						</name>
						<name>
							<surname>de Lange</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Ling</surname>
							<given-names>NR</given-names>
						</name>
						<name>
							<surname>Lowe</surname>
							<given-names>J</given-names>
						</name>
					</person-group>
					<article-title>Evaluation of monoclonal antibodies having specificity for human IgG subclasses: Results of an IUIS/WHO collaborative study</article-title>
					<source>Immunol Lett</source>
					<year>1985</year>
					<volume>10</volume>
					<issue>3-4</issue>
					<fpage>223</fpage>
					<lpage>252</lpage>
				</nlm-citation>
			</ref>
			<ref id="CIT0024">
				<label>24</label>
				<nlm-citation citation-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Jefferis</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Reimer</surname>
							<given-names>CB</given-names>
						</name>
						<name>
							<surname>Skvaril</surname>
							<given-names>F</given-names>
						</name>
						<name>
							<surname>de Lange</surname>
							<given-names>GG</given-names>
						</name>
						<name>
							<surname>Goodall</surname>
							<given-names>DM</given-names>
						</name>
						<name>
							<surname>Bentley</surname>
							<given-names>Tl</given-names>
						</name>
						<etal/>
					</person-group>
					<article-title>Evaluation of monoclonal antibodies having specificity for human IgG subclasses: results of the 2nd IUIS/WHO collaborative study</article-title>
					<source>Immunol Lett</source>
					<year>1992</year>
					<volume>31</volume>
					<issue>2</issue>
					<fpage>143</fpage>
					<lpage>168</lpage>
				</nlm-citation>
			</ref>
			<ref id="CIT0025">
				<label>25</label>
				<nlm-citation citation-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Hasnaoui</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Blanchard</surname>
							<given-names>D</given-names>
						</name>
						<name>
							<surname>Willem</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Loirat</surname>
							<given-names>MJ</given-names>
						</name>
						<name>
							<surname>Lambin</surname>
							<given-names>P</given-names>
						</name>
					</person-group>
					<article-title>Production and properties of mono-clonal antibodies against human IgG isotypes</article-title>
					<source>Hybridoma</source>
					<year>1996</year>
					<volume>15</volume>
					<issue>5</issue>
					<fpage>351</fpage>
					<lpage>358</lpage>
				</nlm-citation>
			</ref>
			<ref id="CIT0026">
				<label>26</label>
				<nlm-citation citation-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Hamilton</surname>
							<given-names>RG</given-names>
						</name>
						<name>
							<surname>Morrison</surname>
							<given-names>SL</given-names>
						</name>
					</person-group>
					<article-title>Epitope mapping of human immunoglobulin-specific murine mono-clonal antibodies with domain- switched, deleted and point-mutated chimeric antibodies</article-title>
					<source>J Immunol Meth</source>
					<year>1993</year>
					<volume>158</volume>
					<issue>1</issue>
					<fpage>107</fpage>
					<lpage>122</lpage>
				</nlm-citation>
			</ref>
			<ref id="CIT0027">
				<label>27</label>
				<nlm-citation citation-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Jefferis</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Reimer</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Skvaril</surname>
							<given-names>F</given-names>
						</name>
						<name>
							<surname>De Lange</surname>
							<given-names>GG</given-names>
						</name>
					</person-group>
					<article-title>WHO/IUIS program for the standardization of immunological reagents: availability of mouse monoclonal antibodies (MAb) to Human IgG subclasses</article-title>
					<source>Immunology</source>
					<year>1988</year>
					<volume>63</volume>
					<fpage>171</fpage>
				</nlm-citation>
			</ref>
			<ref id="CIT0028">
				<label>28</label>
				<nlm-citation citation-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Recht</surname>
							<given-names>B</given-names>
						</name>
						<name>
							<surname>Frangione</surname>
							<given-names>B</given-names>
						</name>
						<name>
							<surname>Franklin</surname>
							<given-names>E</given-names>
						</name>
						<name>
							<surname>Van</surname>
							<given-names>LE</given-names>
						</name>
					</person-group>
					<article-title>Structural studies of a human &#x3B3;3 myeloma protein (Goe) that binds Staphylococcal protein A</article-title>
					<source>J Immunol</source>
					<year>1981</year>
					<volume>127</volume>
					<issue>3</issue>
					<fpage>917</fpage>
					<lpage>923</lpage>
				</nlm-citation>
			</ref>
			<ref id="CIT0029">
				<label>29</label>
				<nlm-citation citation-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Phillips</surname>
							<given-names>DJ</given-names>
						</name>
						<name>
							<surname>Wells</surname>
							<given-names>TW</given-names>
						</name>
						<name>
							<surname>Reimer</surname>
							<given-names>CB</given-names>
						</name>
					</person-group>
					<article-title>Estimation of association constants of 42 monoclonal antibodies to human IgG epitopes using a fluorescent sequential saturation assay</article-title>
					<source>Immunol Lett</source>
					<year>1988</year>
					<volume>17</volume>
					<issue>2</issue>
					<fpage>159</fpage>
					<lpage>168</lpage>
				</nlm-citation>
			</ref>
			<ref id="CIT0030">
				<label>30</label>
				<nlm-citation citation-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Mazza</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Whiting</surname>
							<given-names>AH</given-names>
						</name>
						<name>
							<surname>Day</surname>
							<given-names>MJ</given-names>
						</name>
						<name>
							<surname>Duffus</surname>
							<given-names>WP</given-names>
						</name>
					</person-group>
					<article-title>Development of an enzyme-linked immunosor-bent assay for the detection of IgG subclasses in the serum of normal and diseased dogs</article-title>
					<source>Res Vet Sci</source>
					<year>1994</year>
					<volume>57</volume>
					<issue>2</issue>
					<fpage>133</fpage>
					<lpage>139</lpage>
				</nlm-citation>
			</ref>
			<ref id="CIT0031">
				<label>31</label>
				<nlm-citation citation-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Mazza</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Whiting</surname>
							<given-names>AH</given-names>
						</name>
						<name>
							<surname>Day</surname>
							<given-names>MJ</given-names>
						</name>
						<name>
							<surname>Duffus</surname>
							<given-names>WP</given-names>
						</name>
					</person-group>
					<article-title>Preparation of monoclonal antibodies specific for the subclasses of canine IgG</article-title>
					<source>Res Vet Sci</source>
					<year>1994</year>
					<volume>57</volume>
					<issue>2</issue>
					<fpage>140</fpage>
					<lpage>145</lpage>
				</nlm-citation>
			</ref>
		</ref-list>
	</back>
</article>
